Matches in SemOpenAlex for { <https://semopenalex.org/work/W280339938> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- W280339938 abstract "A comparative, randomised, 12-week (two periods of six weeks) cross-over study including 150 patients (mean age: 63.4 years) suffering from stable but symptomatic (a minimum of three attacks per week) angina pectoris was performed in order to compare the effect on quality of life of two discontinuous nitrate treatments: transdermal 10 mg nitroglycerine patch (12 hours) and long-acting oral 40 mg isosorbide-5-mononitrate (once a day). The efficacy and safety were also compared. The two treatments equally and significantly improved patients' quality of life. The number of attacks and sublingual nitrate consumption significantly decreased under treatment. Attack severity was lower under nitroglycerine than isosorbide-5-mononitrate treatment. Finally, even though nitroglycerine more frequently induced headache than did isosorbide-5-mononitrate (13 cases versus 8), patients, and in particular those having received nitroglycerine treatment in the second period of the study, preferred the transdermal nitroglycerine treatment. In conclusion, results did not show any relevant difference in terms of efficacy or tolerability between the two treatments. Nevertheless, the facility of use and the feeling of protection were better under transdermal nitroglycerine patch than oral isosorbide-5-mononitrate treatment." @default.
- W280339938 created "2016-06-24" @default.
- W280339938 creator A5030192246 @default.
- W280339938 creator A5043725411 @default.
- W280339938 creator A5070355617 @default.
- W280339938 creator A5077489139 @default.
- W280339938 date "2001-10-01" @default.
- W280339938 modified "2023-09-27" @default.
- W280339938 title "Qualité de vie et angine de poitrine. Comparaison des effets de deux dérivés nitrés administrés de façon discontinue : trinitrine 10 mg, 12 heures, par voie transdermique, et isosorbide-5-mononitrate à libération prolongée 40 mg, monoprise, par voie orale☆☆Ce travail a été réalisé avec le concours de Novartis Pharma France." @default.
- W280339938 cites W1585578987 @default.
- W280339938 cites W1968974479 @default.
- W280339938 cites W1973011806 @default.
- W280339938 cites W1992043471 @default.
- W280339938 cites W2000374079 @default.
- W280339938 cites W2002993793 @default.
- W280339938 cites W2019069037 @default.
- W280339938 cites W2043445373 @default.
- W280339938 cites W2082966017 @default.
- W280339938 cites W2136380739 @default.
- W280339938 cites W2138613293 @default.
- W280339938 cites W2149938622 @default.
- W280339938 cites W2218999361 @default.
- W280339938 cites W228126680 @default.
- W280339938 cites W2397475253 @default.
- W280339938 cites W27079662 @default.
- W280339938 cites W3112583453 @default.
- W280339938 cites W3145450432 @default.
- W280339938 cites W57181363 @default.
- W280339938 doi "https://doi.org/10.1016/s0003-3928(01)00034-8" @default.
- W280339938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12555626" @default.
- W280339938 hasPublicationYear "2001" @default.
- W280339938 type Work @default.
- W280339938 sameAs 280339938 @default.
- W280339938 citedByCount "0" @default.
- W280339938 crossrefType "journal-article" @default.
- W280339938 hasAuthorship W280339938A5030192246 @default.
- W280339938 hasAuthorship W280339938A5043725411 @default.
- W280339938 hasAuthorship W280339938A5070355617 @default.
- W280339938 hasAuthorship W280339938A5077489139 @default.
- W280339938 hasConcept C29456083 @default.
- W280339938 hasConcept C71924100 @default.
- W280339938 hasConceptScore W280339938C29456083 @default.
- W280339938 hasConceptScore W280339938C71924100 @default.
- W280339938 hasLocation W2803399381 @default.
- W280339938 hasLocation W2803399382 @default.
- W280339938 hasOpenAccess W280339938 @default.
- W280339938 hasPrimaryLocation W2803399381 @default.
- W280339938 isParatext "false" @default.
- W280339938 isRetracted "false" @default.
- W280339938 magId "280339938" @default.
- W280339938 workType "article" @default.